Paul S. Herendeen
2020 - Valeant Pharmaceuticals International
In 2020, Paul S. Herendeen earned a total compensation of $6M as Former Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International, a 14% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,080,000 |
|---|---|
| Option Awards | $1,050,667 |
| Salary | $1,000,000 |
| Stock Awards | $2,815,424 |
| Other | $20,012 |
| Total | $5,966,103 |
Herendeen received $2.8M in stock awards, accounting for 47% of the total pay in 2020.
Herendeen also received $1.1M in non-equity incentive plan, $1.1M in option awards, $1M in salary and $20K in other compensation.
Rankings
In 2020, Paul S. Herendeen's compensation ranked 1,747th out of 13,090 executives tracked by ExecPay. In other words, Herendeen earned more than 86.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,747 out of 13,090 | 87th |
Division Manufacturing | 668 out of 5,617 | 88th |
Major group Chemicals And Allied Products | 240 out of 2,248 | 89th |
Industry group Drugs | 200 out of 1,948 | 90th |
Industry Pharmaceutical Preparations | 140 out of 1,453 | 90th |
Source: SEC filing on May 2, 2022.
Herendeen's colleagues
We found four more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2020.
2020
Joseph Papa
Valeant Pharmaceuticals International
Chief Executive Officer
2020
Thomas Appio
Valeant Pharmaceuticals International
President Co, Head Bausch + Lomb/International
2020
Christina Ackermann
Valeant Pharmaceuticals International
General Counsel
2020
Sam Eldessouky
Valeant Pharmaceuticals International